Why GoodRx Holdings Inc. [GDRX] Stock Can Run Back to New Highs Quicker Than You Think

GoodRx Holdings Inc. [GDRX] has traded in a range of $33.51 to $64.22 in the last 1 year. As of this writing, the stock is at $38.88, up 3.89%. To check whether the stock’s short-term amount has a thrust, its good to check stock’s recent movement. Over the last week, GDRX shares are -2.98% down with the monthly amount drift of -21.22% and seems bad in a long time frame.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .


On 12, November 2020, GoodRx Releases Third Quarter 2020 Financial Results. According to news published on Yahoo Finance, GoodRx Holdings Inc. (Nasdaq: GDRX), a leading consumer-focused digital healthcare platform in the United States, has released its third quarter 2020 financial results and posted a letter to shareholders on the Overview page of its investor relations website at https://investors.goodrx.com.

Analyst Birdseye View:

The most recent analyst activity for GoodRx Holdings Inc. [NASDAQ:GDRX] stock was on November 18, 2020, when it was Downgrade with an Equal-weight rating from Morgan Stanley, which also raised its 12-month price target on the stock to $36. Before that, on November 19, 2020, RBC Capital Mkts Recapitulated an Outperform rating and elevated its amount target to $56. On October 19, 2020, UBS Initiated a Buy rating and boosted its price target on this stock to $64. On October 19, 2020, SVB Leerink Initiated an Outperform rating and increased its price target to $61. On October 19, 2020, RBC Capital Mkts Initiated a Sector perform rating and increased its price target to $55. On October 19, 2020, Morgan Stanley Initiated an Overweight rating and boosted its amount on this stock to $57. On October 19, 2020, JP Morgan Initiated an Overweight rating and boosted its target amount on this stock to $59. On October 19, 2020, JP Morgan Initiated a Neutral rating and amplified its amount target to $59.

In the past 52 weeks of trading, this stock has oscillated between a low of $33.51 and a peak of $64.22. Right now, the middling Wall Street analyst 12-month amount mark is $50.00. At the most recent market close, shares of GoodRx Holdings Inc. [NASDAQ:GDRX] were valued at $38.88. According to the average price forecast, investors can expect a potential return of 2.62%.


GoodRx Holdings Inc. [NASDAQ:GDRX] most recently reported quarterly sales of 140.45 billion, which represented growth of 38.20%. This company’s Gross Margin is currently 95.10%, its Operating Margin is 10.70%, its Pretax Margin is +21.37, and its Net Margin is +10.93.

The Principal structure of this organization shows its whole liability to whole principal at 197.27 and the whole liability to whole assets at 176.85. It shows enduring liability to the whole principal at 194.50 and enduring liability to assets at 1.74 while looking for an extended time period.

Readers are usually of view to make a close observation to the indicators that support and make resistance before moving to any particular stock. As of now, the company’s stock is sitting at 36.57 points at 1st support level, the second support level is making up to 35.72. But as of 1st resistance point, this stock is sitting at 38.21 and at 39.00 for 2nd resistance point.

GoodRx Holdings Inc. [GDRX] reported its earnings at $0.09 per share in the fiscal quarter closing of 9/29/2020. The Analysts for Wall Street were expecting to report its earnings at $0.08/share signifying the difference of 0.01 and 12.50% surprise value.

Important Ratio’s To Watch

Meanwhile, turning our focus to liquidity, the Current Ratio for GoodRx Holdings Inc. [NASDAQ:GDRX] is 19.60. Likewise, the Quick ratio is also the same, showing Cash ratio at 0.78. Now if looking for a valuation of this stock’s showing 719.62 of P/E (TTM) ratio.